The CITRINE trial is a randomized, open-label, phase 3 clinical trial that compared the effect of adjuvant carboplatin-intensified chemotherapy versus standard chemotherapy on survival in women with high-risk, early-stage, triple-negative breast cancer. In Figure 4 of the paper by Liu and colleagues (BMJ 2025;391:e085457, published 23 Dec 2025), there was an error in the order of the data in the BRCA1/2 gene subsets, resulting in incorrect intergene difference ratios, hazard selection ratios, and HRRs. Moreover, incorrect variables in subgroup analysis caused erroneous hazard ratios for HRR-related genes. These bugs have been fixed. The corrections do not affect the conclusions drawn from the subgroup analysis. This did not change any of the findings or conclusions of the document.